
Combining Avastin With Alecensa Shows Promise in Advanced ALK-Positive Lung Cancer
A phase 2 clinical trial found that adding Avastin (bevacizumab) to Alecensa (alectinib) significantly improved outcomes in advanced anaplastic lymphoma kinase (ALK)-positive lung cancer, which then delayed disease progression and protected the brain …